50 Stock Market News for "INCY"

Incyte Announces Positive Results from a Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo

WILMINGTON, Del.–(BUSINESS WIRE)–<a href="twitter.com/search?q=%24INCY&src=ctag&quot; target="_blank">$INCY</a> <a href="twitter.com/hashtag/wcd2019?src=hash&quot; target="_blank">#wcd2019</a>–Incyte Announces Positive Results from a Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo »

Incyte Announces Positive Results from a Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo

WILMINGTON, Del.–(BUSINESS WIRE)–<a href="twitter.com/search?q=%24INCY&src=ctag&quot; target="_blank">$INCY</a> <a href="twitter.com/hashtag/wcd2019?src=hash&quot; target="_blank">#wcd2019</a>–Incyte Announces Positive Results from a Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo »

Incyte Announces Positive Results from a Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo

WILMINGTON, Del.–(BUSINESS WIRE)–<a href="twitter.com/search?q=%24INCY&src=ctag&quot; target="_blank">$INCY</a> <a href="twitter.com/hashtag/wcd2019?src=hash&quot; target="_blank">#wcd2019</a>–Incyte Announces Positive Results from a Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo »

Amgen Announces BLINCYTO® (blinatumomab) Five-Year Overall Survival Data At EHA 2019

THOUSAND OAKS, Calif., June 15, 2019 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced the five-year overall survival (OS) analysis from the single-arm, Phase 2 BLAST study that evaluated BLINCYTO® (blinatumomab) in patients with minimal residual disease (MRD)-positive acute… »

Data from Incyte’s Inflammation and Autoimmunity Portfolio to be Featured at the 24th World Congress of Dermatology

WILMINGTON, Del.–(BUSINESS WIRE)–Incyte Corporation (Nasdaq:INCY) announces that data from key studies within its inflammation and autoimmunity portfolio will be presented at the 24th World Congress of Dermatology (WCD). This meeting will be held in Milan, Italy from June 10-15, 2019. Presentations will feature 24-week data from a Phase 2 study of ruxolitinib cream in adult patients wi... »

Nasdaq Today: Maintaining Altitude Amid Uncertainty

Shutterstock photo InvestorPlace – Stock Market News, Stock Advice & Trading Tips It was a boring day for the Nasdaq today. While Friday’s session highs did push it to new highs on the week, the index couldn’t close there. The Nasdaq fell 0.24% on the day, but still logged a 3.1% gain for the week. Source: Shutterstock For comparison purposes, the S&P 500 rallied 0.02% an... »

Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market 2019

Dublin, June 21, 2019 (GLOBE NEWSWIRE) — The “T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: A Business, Stakeholder, Technology and Pipeline Analysis” report has been added to ResearchAndMarkets.com‘s offering. This report provides you with a landscape description and analysis of T-cell and natural killer (NK) cell engaging bispecific antibodies as of June 2019.... »

NHL Diffuse Large B Cell Lymphoma Forecast and Market Analysis 2018-2034 – CAR-T Therapies will Become the Highest-Selling Class – ResearchAndMarkets.com

The “NHL: Diffuse Large B Cell Lymphoma Forecast and Market Analysis to 2034” drug pipelines has been added to ResearchAndMarkets.com‘s offering. Diffuse large B-cell lymphoma (DLBCL) is a form of hematological malignancy that affects B lymphocytes. This cancer is the most common type of non-Hodgkin’s lymphoma (NHL), accounting for about one-third of all newly diagnosed cas... »

The World Market for Leukemia Therapeutics 2019-2024 – Novartis is Leading the Market, Owing to Its Strong Sales Channel & Innovative Therapies

Dublin, June 20, 2019 (GLOBE NEWSWIRE) — The “Leukemia Therapeutics Market by Type (CLL, ALL, CML, AML), Treatment Type (Chemotherapy & Targeted Drugs), Mode of Administration (Oral, Injectable), Molecule Type (Small Molecules, Biologics), Gender, and Region – Global Forecast to 2024” report has been added to ResearchAndMarkets.com‘s offering. The leukemia therape... »

Clinical Results of Fully Human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by IASO BIO and Innovent Presented at the 2019 ASCO and EHA Annual Meetings

NANJING, China–(BUSINESS WIRE)–IASO Biotherapeutics (IASO BIO), one of the top biotechnology innovators, announced their potential best-in-class therapy back-to-back at two of the most prestigious clinical meetings in the worlds of hematology and oncology, the American Society of Clinical Oncology (ASCO) Annual Meeting 2019 in Chicago, Illinois, May 31-June 4 [Abstract#8013; Monday, Ju... »

Clinical Results of Fully Human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by IASO BIO and Innovent Presented at the 2019 ASCO and EHA Annual Meetings

NANJING, China–(BUSINESS WIRE)–IASO Biotherapeutics (IASO BIO), one of the top biotechnology innovators, announced their potential best-in-class therapy back-to-back at two of the most prestigious clinical meetings in the worlds of hematology and oncology, the American Society of Clinical Oncology (ASCO) Annual Meeting 2019 in Chicago, Illinois, May 31-June 4 [Abstract#8013; Monday, Ju... »

Encore Boston Harbor Offers Online Hub for Trip Planning at EncoreBostonHarbor.com/Go

Public and shared transportation services are available for guests traveling from Greater Boston, Eastern Massachusetts, and out of state Encore Boston Harbor resort visitors from New England and beyond can visit the Five Star resort using public and shared transportation, with convenient choices and directions laid out by region at www.EncoreBostonHarbor.com/go. Encore Boston Harbor has introduce... »

Global Mesothelioma Market Spotlight Report 2019: 10 Year Prevalence Forecast, Licensing and Acquisition Deals, & Drug-Specific Revenue Forecasts

DUBLIN, June 18, 2019 /PRNewswire/ — The “Market Spotlight: Mesothelioma” report has been added to ResearchAndMarkets.com‘s offering. This Market Spotlight report covers the mesothelioma market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition... »

Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by Innovent and IASO BIO Presented at 2019 ASCO and EHA Annual Meetings

CT103A is an anti-BCMA CAR-T co-developed by Innovent and IASO BIO for the treatment of Relapsed/Refractory Multiple Myeloma (RRMM). The data of CT103A presented at both conferences show an impressive efficacy results, persistence and safety profile and an objective response rate (ORR) of 100%. The data are especially encouraging for patients who relapsed from a prior CAR-T treatment with mouse-ba... »

Market Close Report: NASDAQ Composite index closes at 7,845.02 up 48.36 points

Shutterstock photo Monday’s session closes with the NASDAQ Composite Index at 7,845.02. The total shares traded for the NASDAQ was over 1.9 billion. Advancers stocks led declining by 1.17 to 1 ratio. There were 1692 advancers and 1450 decliners for the day. On the NASDAQ Stock Exchange 41 stocks reached a 52 week high and 53 those reaching lows totaled. The most active, advancers, decliners,... »